Maduck Sean sold $2.9M of CORT
Maduck Sean (See Remarks) sold 25,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $116.26 ($115.54–$116.55, $2.91M total) across 3 trades over 2026-10-01 to 2026-10-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed $2.9M sale reduces insider ownership and may prompt short‑term price weakness, though the pre‑arranged nature tempers the signal.
Market read
Primary insider sale; modest impact on CORT's share price, limited broader market effect.
What to watch
Potential upcoming clinical data releases or FDA decisions could offset the negative signal from the insider sale.
Background
Form 4 filings disclose insider trades; a 10b5‑1 plan sale by an officer is a routine but noteworthy event for shareholders.
Ticker impact
Officer Maduck Sean sold 25,000 shares for $2.9M via a 10b5‑1 plan, reducing his stake to 9,938 shares.
likely pressure as the market prices in the insider sell
A $2.9M open‑market sale by an officer is a material insider transaction that can trigger short‑term selling pressure.
Market effects
Minimal; the sale is specific to Corcept and does not affect the broader pharma sector.
None; the transaction is company‑specific.
Low; only relevant to investors holding CORT.
Counterpoint
The sale may be purely procedural under a pre‑arranged 10b5‑1 plan and not indicative of future performance.
Key entities
- OfficerMaduck Sean
Insider who sold 25,000 CORT shares via a 10b5‑1 plan.
- CompanyCorcept Therapeutics Inc.
Biopharma company whose ticker is CORT.
